The Cetuximab Market, a vital segment within the oncology therapeutics landscape, is experiencing sustained growth, driven by the increasing global prevalence of metastatic colorectal cancer (mCRC) and head and neck cancer (HNC). Cetuximab, a chimeric monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), is a cornerstone in the treatment protocol for...